



**ISSN:2229-6107**



**INTERNATIONAL JOURNAL OF  
PURE AND APPLIED SCIENCE & TECHNOLOGY**

**E-mail :**  
**editor.ijpast@gmail.com**  
**editor@ijpast.in**

**[www.ijpast.in](http://www.ijpast.in)**

# Reactions to the COVID 19 vaccine: detecting and describing them

Mr. USV Vinod, Mr. GSVR Abhishek, Dr. Suresh Kopparthi,

## Abstract

Many nations have made significant efforts, including vaccine development, to combat the spread of COVID-19. This publication aimed to provide a comprehensive review of COVID-19 vaccines, including their history, current uses, and potential pitfalls. This article surveyed previous attempts to track the evolution of the COVID-19 immunogen.

## 1. INTRODUCTION

In a first for 2019, on December 31st, China announced the onset of a new corona virus illness caused by the severe acute respiratory syndrome corona virus type 2 (SARS-CoV-2).<sup>1</sup>

The World Health Organization (WHO) will hold its

On February 11, 2019, the World Health Organization (WHO) officially designated the new corona virus pneumonia outbreak Corona virus illness 2019. (COVID-19).

The global pandemic influenza A (COVID-19) had catastrophic effects on almost every nation. Even in moderate instances and asymptomatic infections, the new corona virus is very infectious and spreads rapidly. The potential for "hidden" transmission in public spaces and hospitals is high.

At some point, the virus might morph into a mild seasonal pandemic.

Due to the broad vulnerability of the population, it is unknown how the virus is transmitted from the host to the individual even if the infection is eradicated. A recurrence of the disease is possible, as are recurring outbreaks. Vaccines must be given as soon as humanly practical. There are about 7.8

billion individuals on the planet who might get infected with SARSCoV-2 or experience the devastating effects of COVID-19. To stop the spread of COVID-19 and ensure that it doesn't happen again, scientists are eagerly awaiting the creation of a safe and effective vaccine. The World Health Organization (WHO) now lists over 200 COVID-19 vaccines as being under development. High hopes are placed on preventative COVID-19 vaccinations. In 2021, three vaccines may be available on the market if they have been shown to be efficacious and safe in late-stage clinical testing. Several vaccines, including BNT162b2 from Pfizer-BioNTech and mRNA-1273 from Moderna, have been given the green light for commercial release.

## 2. METHODOLOGY

Both humoral and cellular immunity must be considered in the development of COVID-19 vaccines. Since COVID-19 is transmitted mostly via the respiratory system and direct touch, more attention should be made to the function of mucosal immunity in warding off viral infections.

Assistant Professor<sup>1,2</sup>, Professor and Principal,<sup>3</sup>

Department of Computer Science and Engineering,

Bhimavaram Institute of Engineering and Technology, Bhimavaram, Andhra Pradesh, India.

E.mail id: [satyamca41@gmail.com](mailto:satyamca41@gmail.com), E.mail id: [abhishek.gajula@gmail.com](mailto:abhishek.gajula@gmail.com),

E.mail id: [sureshkgri@gmail.com](mailto:sureshkgri@gmail.com)

attention. There are four structural proteins inside the virus. There are four types of viral proteins: the nucleocapsid N protein, the membrane/matrix protein, the nucleoprotein (spike) S protein, and the envelope (E) protein. Subunits S1 and S2 are found within the S protein. Viruses infect cells when their S protein attaches to certain receptors. 5-7

The virus's ability to invade cells may be thwarted by a neutralising antibody directed against the S protein.

8

S protein is the most crucial target antigen in vaccine development because of its ability to efficiently trigger T-cell immune response. Additionally, it has been shown that N and M proteins stimulate an effective cellular immunological response in the body. 9-11

For a respiratory virus, SARS-CoV-2 is uncommon since it interacts to a receptor, ACE2 (ACE2). ACE2 is widely expressed, notably in the lungs, the digestive system, and the brain. 14 Therefore, SARS-CoV-2 has a larger biological distribution than other respiratory viruses and may cause substantial harm outside of the respiratory system. It has deleterious effects on your gastrointestinal tract, bloodstream, brain, and genitourinary system. Multiple symptom shifts, including dyspnea, headache, diarrhoea, venous thromboembolism, and elevated blood pressure, result from the widespread distribution of ACE2 receptors. 15 S protein interacts with host cell ACE2 to mediate infection. While the S2 subunit facilitates viral fusion with cells throughout infection, the S1 subunit is important for initial attachment to the host cells via the ACE2 receptor. 16 Antibodies attaching to the proper epitope on the S protein have the potential to be neutralising and impede inter cellular viral propagation, making it a popular vaccination target. 16

### 3. TYPES OF VACCINES

Here are some broad groups into which we may place the vaccines that are presently under development. Vaccines come in a variety of kinds, each with its own set of benefits and

#### DNA vaccines

DNA vaccines are similar to viral infections in that they may enter cells and then utilize the host's protein translation machinery to create

the desired antigens. It is an endogenous immunogen that may simultaneously stimulate both humoral and cellular immune responses. Consider the benefits of nucleic acid

DNA vaccines provide a higher level of security since they do not use live viruses. DNA vaccines include the direct administration of plasmids with genes encoding foreign antigens into people or animals. These plasmids have eukaryotic expression elements that enable the antigen proteins to be expressed in host cells and elicit immune responses to prevent illness. 17

The double-strand DNA molecules used in plasmid DNA are more durable than the virus and may be freeze-dried for extended storage, making plasmid DNA production a very simple operation. The ineffectiveness of the DNA vaccine may be attributed to the immunization process. After vaccination, the vast majority of the vaccine is found in the inter cellular space, where just a tiny fraction may enter cells to generate protein immunogen, resulting in a much diminished immunological response. The primary hindrance of the plasmid DNA vaccine is the need for transfection methods due to its poor transfection effectiveness. Inovio's COVID-19 vaccine candidate, INO-4800, employs the utilization of a portable electroporation equipment called CELLECTRA. 18 Vaccine and electrodes will be administered intermediately. The plasmid is introduced into the cell by first applying an electric pulse to the cell membrane, which then opens. While using a tried-and-true technology may speed up the beginning of clinical studies, it also introduces new challenges to widespread immunization. Inducing systemic immune responses is a strength of nucleic acid vaccines, but their immunogenicity is low, and it is difficult to generate mucosal immune responses. Although there have been DNA vaccinations for animals, none have been licenced for use in humans. The immunological effects of a vaccination may be enhanced by using it in conjunction with additional immunizations.

mRNA vaccinations 3.2 |

Theoretically, mRNA vaccines are less dangerous than DNA vaccines since they don't have to penetrate the nucleus to accomplish target antigen production. Development of mRNA vaccines has accelerated in recent years. Even though phase I clinical assessment of rabies and influenza mRNA vaccines<sup>19,20</sup> is complete, the immunological effect is not sufficient due to factors including a relatively

high percentage of headaches, weariness, and side effects like muscular discomfort. The vaccine's protective effects lasted less than a year and there was no detectable cellular immune response. So, it's important to boost the short- and long-term protection of mRNA vaccines. There is currently no mRNA-based vaccination available. However, mRNA vaccines are still in the early stages of investigation and development.

The creation of COVID-19 mRNA vaccines has been rapidly embraced by several institutes both at home and abroad. The mRNA vaccine led the way in starting a phase I clinical trial since it was created by the National Institute of Allergy and Infectious Diseases (NIAID) and Moderna. The mRNA-1273 vaccine developed by Moderna encodes a transmembrane anchor and the whole S1S2 cleavage site, ensuring that only the perfusion form of the S antigen is expressed. 2

## **Non-replicating viral vector vaccines**

Both Casino and Oxford/AstraZeneca are now using Adenovirus (Ad) as a viral vector. The DNA genomes of the common cold viruses known as adenoviruses are double-stranded. The vaccine developed by Casino uses Ad type 5 (Ad5) and is known as Ad5-nCoV. Twenty-two Ad5-nCoV are capable of encoding the complete S protein of

SARS-CoV-2. This gene was constructed using the Wuhan-Hu-1 SARS-CoV-2 sequence, and it was cloned into an E1- and E3-deficient Ad5 vector, together with the tissue plasminogen activator signal peptide. 16 Although this vaccination has a high success rate, it may not protect those with recessive infectious viruses.

## **Inactivated vaccines**

The first vaccinations were inactivated and they still remain the most common kind used today. They are simple to make and effective in stimulating the body's humoral immune system.

They are often used as test subjects for novel infectious illnesses. Inactivated

Formaldehyde, -propiolactone, and UV light are the three most common inactivation techniques used to produce vaccines. Mice, hamsters, ferrets, and monkeys all develop significant titers of neutralising antibodies

after receiving inactivated vaccinations against SARS and MERS. Phase I clinical studies of the inactivated SARS vaccine have shown that it is safe for human use and may prompt the development of neutralising antibodies. 23 On the other hand, inactivated vaccinations seldom elicit a robust T-cell immune response. Studies have demonstrated that inactivated vaccinations for SARS and MERS do not prompt the body to create functional cellular immune responses. 24,25 While substantial levels of neutralising antibodies in the serum are generated, the resulting protection is insufficient. 25 It has been shown in several investigations that the inactivated MERS vaccination might trigger severe allergic responses in the lungs of mice. 26 The SARS-CoV-2 vaccine now in use is an inactivated Vero cell vaccination. There is also a danger to biological safety since vaccine manufacturing necessitates working with large volumes of live viruses.

## **Live attenuated vaccines**

Unlike killed vaccines, live attenuated vaccines maintain the immunogenicity and reproduction capacity of the virus while having reduced its virulence by point mutation or deletion of a critical viral protein. The vaccines in this programme have excellent immunogenicity, meaning they can produce a protective immune response in the body as a whole and in the mucosal lining of the mouth and throat. Many live attenuated vaccinations, such as those for yellow fever, smallpox, and measles, have been available to the public for some time.

Chickenpox, measles, polio, mumps, and rubella. It has been shown that the SARS live attenuated vaccine may regain its virulence after repeated passage in cells or animals, indicating that there is a higher biological safety risk associated with this vaccination strategy. 27 This approach is not suggested at this time for the creation of a vaccine against COVID-19 since there is not enough data to guarantee that live attenuated vaccines will not recover strength.

## **Sub unit vaccines**

Subunit vaccines, which are made of pure recombinant proteins, are often regarded as the safest kind of immunisation. Several subunit vaccinations, such as those for hepatitis B, hepatitis E, and human papillomavirus, are

now available. Components of SARS and MERS

High-titer neutralising antibodies may be induced by vaccination in mice, and a mucosal immune response can be induced by nasal or oral vaccination, making it more difficult for the virus to spread via the respiratory system. Data also show that mucosal immunisation is more effective in preventing disease than intramuscular inoculation. 28-31

However, subunit vaccinations are ineffective at creating sensitised cytotoxic T lymphocytes because they include a non-endogenous antigen that cannot be delivered by MHC-I. (CTL). The COVID-19 subunit vaccine is most effective when administered in combination with other platform vaccines due to the critical importance of cellular immunity in eradicating coronavirus infections. In order to stimulate mucosal immune responses, vaccinations delivered through the nasal and oral mucosal routes are encouraged.

## **Trained immunity-based vaccines**

Vaccines that rely on acquired immunity may stimulate the adaptive immune system and provide protection against certain pathogens. 32,33 At now, TB may be prevented with the use of a vaccination called Bacille Calmette-Guerin (BCG).

It will take some time for clinical evaluations to determine whether or not the vaccine can successfully establish trained immunity against COVID-19.

34 The BCG vaccination may be effective against COVID-19, but it still has to overcome some significant obstacles. In other words, the quality standards at which the BCG vaccine is produced will differ from nation to country, and it is unclear whether or not these requirements are necessary to give protection against COVID-19.3.

## **4. QUESTIONS AND THOUGHTS**

Vaccine research and development is perpetually fraught with a wide range of challenges.

Later vaccination implementation and assessment stands out among them.

### **4.1 Problems with Dosage**

Finding the optimal dosage that strikes a balance between safety and effectiveness has proven difficult in many phase III trials, leading to their failure.

36 The mRNA vaccine, for instance, has not yet had its dosage protocol fully analysed. Antibody titers do not seem to be considerably greater with the 250-g dosage compared to the 100-g dose, but it is associated with a higher incidence of major systemic adverse effects. The study authors advised cautiously assessing 100 g doses or less to determine the regimen that optimally balances the vaccine's benefits and risks. Another factor in this scenario that must be taken into account while determining the proper dose is the patient's age. Age-related reduction in immunological function may increase the risk of severe COVID-19 in the elderly and reduce the effectiveness of vaccines. Can the elderly be protected well against COVID-19 with a standard dosage, or do higher doses, as shown with flu vaccination, seem to be necessary? Fixing these issues might take some time.

In addition to the benefits, the vaccination might cause some unpleasant side effects including fever, sore muscles, and a rash.

38,39 WHO's COVID-19 vaccine road map includes desired and most fundamental needs such as vaccination safety and efficacy as strategic goals. 40 "safety and reactogenicity sufficient to provide a highly favourable benefit/risk profile in the context of the observed vaccine efficacy" and "only mild, transient related to adverse vaccination events without serious adverse events" are two of the most sought-after criteria for vaccine safety and reactogenicity. Vaccines must meet minimal standards for safety and reactogenicity, such as having more positive effects than negative ones. The long-term findings demonstrated a level of safety enough to give extremely attractive benefits/risk characteristics in the context of the reported vaccination effectiveness and immunogenicity. Vaccination-related adverse effects were mild or nonexistent. Preferable standards for efficacy include a protective effectiveness in the population of at least 70% and the same for the older population. If it's meant to stop an epidemic, the treatment's protective effects must show up in two weeks and endure for at least a year. Among the most fundamental need is a population-level preventive impact of

at least 50% over a period of at least six months.

Evaluation of Efficacy and Safety in Human Subjects (endpoint observation)

Development of a vaccination against COVID-19 has to take safety into account as a top priority. The primary concern of vaccine research, development, and testing is the safety of the healthy subjects who serve as the vaccines' intended recipients. To help guide vaccine production and clinical trials, the State Drug Administration published "Notice on the Guidelines for the Classification of Adverse Events in Clinical Trials of Preventive Vaccines"<sup>41</sup> and other rules. Prior efforts to create vaccinations against infectious diseases, such as inactivated measles and respiratory syncytial virus, led to an increase in antibody-dependent illness.<sup>42</sup> Therefore, it is important to consider the potential for comparable immunopathological responses while researching COVID-19 vaccines. We need to keep an eye on things for a while to make sure everything is safe.

Trialists have the freedom to choose which symptoms and levels of severity will prompt virologic testing, notwithstanding the FDA's recommendation that the COVID-19 endpoint be defined as virologically proven SARS-CoV-2 infection with one or more of 11 symptoms. Determining a standard COVID-19 endpoint for usage across trials is crucial for facilitating meta-analyses of trial data and for making sense of individual study findings.

To undertake an uniform and thorough assessment of benefits and dangers, as well as to provide aggregated data for analysis of the immunosurrogate endpoint, it is crucial that all studies employ the same set of clinical endpoints for assessing vaccine effectiveness. Whatever the case may be, COVID-19 and severe COVID-19 should be investigated as separate clinical outcomes in all vaccination effectiveness studies. Long-term protection against these two outcomes, notably the severe COVID-19, requires extensive follow-up of all individuals. We need more counts of endpoints to accurately assess vaccination effectiveness. There may be a transition toward more asymptomatic SARS-CoV-2 infections as a result of vaccination, thus it's important that trial designs allow for assessing vaccine effectiveness against this outcome.

Injection of Vaccines | Section 4.4

Vaccines' success in reducing the incidence of disease-related disability and mortality

provides compelling evidence that they should be used to manage COVID-19.

44,45 Lack of vaccines is no longer a problem, but people's reluctance to be vaccinated is.

Two and a half hundred and thirty-four of the 8,969 non-vaccinated workers at the University of Texas Southwestern Medical Center contracted the disease (2.61%), whereas just four of the 8,121 vaccinated employees did (0.05%).

46,47

Despite a dramatic surge of the B.1.1.7 variant (see up to 80% of cases), the incidence of new cases of COVID-19 among the medical personnel who got two doses of the vaccination reduced considerably in a Jerusalem hospital. This evidence demonstrates that immunization has effectively shielded health care providers from dangerous situations.<sup>48</sup> Vaccination is, hence, crucial in efforts to stop pandemics across the world.

## **Immunizations for Travel**

It stands to reason that entry and exit personnel will be the primary res ponders to future epidemics if the current outbreak is contained and the source of the pandemic is mostly external.

Vaccinations should be administered to close contacts of entry employees as part of the strategy's implementation.

## **Post-Exposure Immunization**

If it is shown that the COVID-19 vaccine may prevent or lessen the severity of illness symptoms in exposed patients, a post-exposure vaccination plan targeting close contacts of confirmed COVID-19 cases may be implemented. Therefore, to ascertain the scientific character of post-exposure vaccination, it is vital to examine the protective efficacy of COVID-19 vaccines, particularly vaccines generated by innovative technology.

## **Pre-exposure vaccination**

Medical personnel working in fever clinics are among those at risk of contracting COVID-19 because of their proximity to infected patients.

Exposure pre-immune preventive techniques should be taken by pathogen testing people, contact individuals from COVID-19 endemic countries, etc.

Recommendation:4.8 | Urgent vaccination

To verify the efficacy of the COVID-19 vaccine in an emergency vaccination setting in the event of a COVID-19 outbreak, an

The people living in the epidemic zone may benefit from an immediate vaccination plan. Therefore, it is important to conduct the impact assessment of emergency vaccination, particularly the effect evaluation of the implementation of the ring immunization strategy, in the nascent stage of vaccine marketing.

In addition to the aforementioned four options for pandemic vaccination, the fact that the whole population is vulnerable to COVID-19 distinguishes it from the H1N1 pandemic.

49 Targets and immunization techniques for mass pandemic vaccination are determined after careful assessment of protection objectives, decreasing mortality, and cluster outbreaks, in the case of vaccine delivery in batches.

## 5. CONCLUSION

In a nutshell, the welfare of practically every nation and citizen depends on the successful creation of the COVID-19 vaccine. Researching the vaccines' immunogenicity and immunological reactivity is a top priority.

## REFERENCES

- 1) Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: Origin, transmission, and characteristics of human corona viruses. *J Adv Res.* 2020;24:91-98.
- 2) WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel corona virus (2019-nCoV) [EB/OL]. (2020-01-23) [2020-02-25]. [https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
- 3) Draft landscape of COVID-19 candidate vaccines; <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>.
- 4) Clinical Trials. Draft landscape of COVID-19 candidate vaccines [EB/OL]. [2020 - 09 - 29]. <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>.
- 5) Li F, Li W, Farzan M, et al. Structure of SARS corona virus spike receptor-binding domain complexed with receptor. *Science.* 2005;309(5742):1864-1868.
- 6) Agnihothram S, Gopal R, Yount BL Jr, et al. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome corona virus and other corona viruses to develop vaccine platforms for the rapid response to emerging corona viruses. *J Infect Dis.* 2014;209(7):995-1006.
- 7) Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS corona virus. *Nature.* 2003;426(6965):450-454.
- 8) Du L, Yang Y, Zhou Y, et al. MERS-CoV spike protein: a key target for antivirals. *Expert Opin Ther Targets.* 2017;21(2):131-143.
- 9) Wang Z, Yuan Z, Matsumoto M, et al. Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome corona virus in BALB/c mice. *Biochem Biophys Res Commun.* 2005;327(1):130-135.
- 10) Zhu MS, Pan Y, Chen HQ, et al. Induction of SARS-nucleoproteinspecific immune response by use of DNA vaccine. *Immunol Lett.* 2004;92(3):237-243.
- 11) Kim TW, Lee JH, Hung CF, et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome corona virus. *J Virol.* 2004;78(9):4638-4645.
- 12) Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. *Curr Opin Pharmacol.* 2006;6(3):271-276.
- 13) Wang J, Zhao S, Liu M, et al. ACE2 expression by colonic epithelial cells is associated with viral infection. *Immunity Energy Metab. medRxiv* 2020, 2020.02.05.20020545.
- 14) Xia H, Lazartigues E. Angiotensin-converting enzyme 2 in the brain: properties and future directions. *J Neurochem.* 2008;107(6):148214-148294.
- 15) Zhang Y, Geng X, Tan Y, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. *Biomed Pharmacother.* 2020;127: 110195.
- 16) Astuti I, Ysrafil. Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2): an overview of viral structure and host response. *Diabetes Metab Syndr.* 2020;14(4):407-412.
- 17) Suschak JJ, Williams JA, Schmaljohn CS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. *Hum Vaccin Immunother.* 2017;13(12):2837-2848.
- 18) INOVIO Expands manufacturing of COVID-19 DNA vaccine INO4800 With New Funding from CEPI [Internet]. [cited 2020 May 18]. Available from: <http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Expands-Manufacturing-of-COVID-19-DNA-Vaccine-INO-4800-With-New-Fundingfrom-CEPI/default.aspx>
- 19) Alberer M, Gnäd-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. *Lancet.* 2017;390(10101):1511-1520.
- 20) Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are